Kudos to Juanita Crook and colleagues for attempting to wrestle some scientific sense into recommendations for seed implant brachytherapy for prostate cancer.1 Unfortunately, there are no data from ...

This Review highlights current areas of controversy and development in the field of transperineal permanent prostate seed implantation brachytherapy (PPI), in particular the technological evolution of ...

Aside from skin cancer, prostate cancer is the most common cancer for men. About one in seven men will be diagnosed with the disease in their lifetime, and prostate cancer is the third leading cause ...

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases, according to new research.

Purpose: To summarise the practical aspects of the development of techniques of interstitial permanent prostate brachytherapy (PPB) implantation. Prostate brachytherapy dates back to Pasteau's ...

Background: Brachytherapy (permanent implantation of radioactive seeds) has emerged as an alternative to existing standard therapy with radical prostatectomy or external beam radiotherapy in the ...

CHICAGO, Sept. 2 (UPI) -- Two studies say brachytherapy -- radiation seed implants -- is a superior treatment for early-stage prostate cancer, officials at a Chicago non-profit say. The Prostate ...

Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient. Trends among medical ...

In the first significant advancement in brachytherapy in more than 15 years, physicians at UW Medical Center have today (Oct. 26) implanted for the first time in the world a new type of radioactive ...

Brachytherapy is ideally suited for treatment of early prostate cancer and was first used as a treatment modality 60 years ago. Brachytherapy is used to treat cancers of the head and neck, breast, ...

OXFORD, Conn.--(BUSINESS WIRE)--BrachySciences, the leader in providing innovative medical devices for the treatment of early stage prostate cancer, has announced a distribution agreement with IsoRay ...

CHICAGO--(BUSINESS WIRE)--Brian Moran, MD, founder and principal of the Chicago Prostate Cancer Center (CPCC) presented the results of his two-year investigation into key characteristics of Cesium-131 ...